相关实验视频

Updated: Jun 10, 2025

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.0K

通过孟德尔的随机化分析,探索宫癌 in situ 和抗体介导免疫反应之间的相互作用机制

Junfei Li1, Lihuang He2, Qun He3

  • 1Department of Gynecology, Affiliated Hospital (Clinical College) of Xiangnan University, Chenzhou, 423000, People's Republic of China.

Discover oncology
|October 17, 2024
PubMed

Insights

这项研究揭示了抗体介导的免疫反应和 in situ 子宫癌之间的双向因果关系. 这些发现支持通过了解免疫系统相互作用来预防和治疗宫癌的新策略.

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 遗传学 遗传学 是一个

背景情况:

  • 在位子宫癌 (CIS) 是侵袭性宫癌的前体.
  • 了解免疫反应和CIS之间的相互作用对于开发有效的预防和治疗策略至关重要.

研究的目的:

  • 调查抗体介导免疫反应和宫癌之间的因果关系.
  • 为预防和治疗宫癌在现场提供科学基础.

主要方法:

  • 使用双向的门德尔随机化 (MR) 方法.
  • 采用全基因组关联研究 (GWAS) 数据用于 in situ 子宫癌和抗体介导免疫反应.
  • 应用了多种统计方法,包括反变量加权 (IVW),MR-Egger回归,加权中位数和加权模式.

主要成果:

  • 预先的MR分析发现了在抗体介导免疫反应中的特定SNP和in situ宫癌之间存在显著的因果关系.
  • 反向MR分析表明,在位子宫癌会影响与抗体介导免疫反应相关的多个SNP.
  • 在前期和逆向分析中,一些SNP显示出显著的积极或明显的影响趋势.

结论:

  • 证实了抗体介导免疫反应和宫癌在位之间明显的双向因果关系.
  • 在免疫反应和宫癌之间阐明的相互作用机制 in situ.
  • 建议开发针对性预防和控制宫癌 in situ 战略的潜在途径.
抽象的

No abstract available in PubMed .

关键词:
抗体介导的免疫反应.在位子宫癌的宫癌.全基因组关联研究研究.门德尔的随机化

更多相关视频

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

297

相关概念视频

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K